The cancer preventive effects of edible mushrooms

Anti-Cancer Agents in Medicinal Chemistry

Volumn 12, Issue 10, 2012, Pages 1255-1263

  Xu, Tongtong ^a   Beelman, Robert B ^a   Lambert, Joshua D ^a  

^a PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

Agaricus spp.; Apoptosis; Button mushrooms; Cancer prevention; Grifola frondosa; Lentinus edodes; Maitake; Mushrooms; Oyster; Pleurotus ostreatus; Polyphenols; Proteoglycans; Shiitake

Indexed keywords

AGARICUS BLAZEI EXTRACT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CASPASE 7; CD31 ANTIGEN; CONJUGATED LINOLEIC ACID; CYTOCHROME C; ETOPOSIDE; FLUOROURACIL; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 2; KI 67 ANTIGEN; LENTINAN; MAITAKE POLYSACCHARIDE; MITOMYCIN C; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PACLITAXEL; PROCASPASE 3; TEGAFUR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

AGARICUS BISPORUS; AGARICUS BLAZEI; ALLERGIC REACTION; ALOPECIA AREATA; ANOREXIA; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLADDER CARCINOMA; BLOATING; BREAST CANCER; CANCER GROWTH; CHOLESTEROL BLOOD LEVEL; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG WITHDRAWAL; EDIBLE MUSHROOM; FOOD INTAKE; GRIFOLA FRONDOSA; HEADACHE; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNE RESPONSE; JOINT SWELLING; LENTINULA EDODES; LIVER INJURY; MUSCLE CRAMP; NAUSEA; NEOPLASM; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PLEUROTUS OSTREATUS; PROSTATE CANCER; SIDE EFFECT; WEAKNESS;

AGARICALES; AGARICUS; ANIMALS; ANTICARCINOGENIC AGENTS; BIOLOGICAL AGENTS; DIET; GRIFOLA; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PLEUROTUS; SHIITAKE MUSHROOMS;

EID: 84870189944     PISSN: 18715206     EISSN: 18755992     Source Type: Journal    
DOI: 10.2174/187152012803833017     Document Type: Article

References (89)

1. The National Agricultural Statistics Service; Agricultural Statistics Board; United States Department of Agriculture, Eds.; In Mushrooms; 2011; pp 1.
2. Chang, S. T.; Buswell, J. A. Mushroom nutriceuticals. World J. Microbiol. Biotechnol., 1996, 12, 473-476.
3. Zhang, M.; Huang, J.; Xie, X.; Holman, C. D. Dietary intakes of mushrooms and green tea combine to reduce the risk of breast cancer in Chinese women. Int. J. Cancer, 2009, 124, 1404-1408.
4. Hong, S. A.; Kim, K.; Nam, S. J.; Kong, G.; Kim, M. K. A casecontrol study on the dietary intake of mushrooms and breast cancer risk among Korean women. Int. J. Cancer, 2008, 122, 919-923.
5. Shin, A.; Kim, J.; Lim, S. Y.; Kim, G.; Sung, M. K.; Lee, E. S.; Ro, J. Dietary mushroom intake and the risk of breast cancer based on hormone receptor status. Nutr. Cancer 2010, 62, 476-483.
6. Zeegers, M. P.; Goldbohm, R. A.; van den Brandt, P. A. Consumption of vegetables and fruits and urothelial cancer incidence: a prospective study. Cancer Epidemiol. Biomarkers Prev., 2001, 10, 1121-1128.
7. Schulz, M.; Lahmann, P. H.; Boeing, H.; Hoffmann, K.; Allen, N.; Key, T. J.; Bingham, S.; Wirfalt, E.; Berglund, G.; Lundin, E.; Hallmans, G.; Lukanova, A.; Martinez Garcia, C.; Gonzalez, C. A.; Tormo, M. J.; Quiros, J. R.; Ardanaz, E.; Larranaga, N.; Lund, E.; Gram, I. T.; Skeie, G.; Peeters, P. H.; van Gils, C. H.; Bueno-de-Mesquita, H. B.; Buchner, F. L.; Pasanisi, P.; Galasso, R.; Palli, D.; Tumino, R.; Vineis, P.; Trichopoulou, A.; Kalapothaki, V.; Trichopoulos, D.; Chang-Claude, J.; Linseisen, J.; Boutron-Ruault, M. C.; Touillaud, M.; Clavel-Chapelon, F.; Olsen, A.; Tjonneland, A.; Overvad, K.; Tetsche, M.; Jenab, M.; Norat, T.; Kaaks, R.; Riboli, E. Fruit and vegetable consumption and risk of epithelial ovarian cancer: the European Prospective Investigation into Cancer and Nutrition. Cancer Epidemiol. Biomarkers Prev., 2005, 14, 2531-2535.
8. Lucas, E. H.; Ringler, R. L.; Byerrum, R. U.; Stevens, J. A.; Clarke, D. A.; Stock, C. C. Tumor inhibitors in Boletus edulis and other Holobasidiomycetes. Antibiot. Chemother., 1957, 7, 1-4.
9. Martin, K. R.; Brophy, S. K. Commonly consumed and specialty dietary mushrooms reduce cellular proliferation in MCF-7 human breast cancer cells. Exp. Biol. Med. (Maywood), 2010, 235, 1306-1314.
10. Grube, B. J.; Eng, E. T.; Kao, Y. C.; Kwon, A.; Chen, S. White button mushroom phytochemicals inhibit aromatase activity and breast cancer cell proliferation. J. Nutr., 2001, 131, 3288-3293.
11. Toth, B.; Raha, C. R.; Wallcave, L.; Nagel, D. Attempted tumor induction with agaritine in mice. Anticancer Res., 1981, 1, 255-258.
12. Nagaokaa, M. H.; Nagaoka, H.; Kondo, K.; Akiyama, H.; Maitani, T. Measurement of a genotoxic hydrazine, agaritine, and its derivatives by HPLC with fluorescence derivatization in the agaricus mushroom and its products. Chem. Pharm. Bull. (Tokyo), 2006, 54, 922-924.
13. Toth, B.; Sornson, H. Lack of carcinogenicity of agaritine by subcutaneous administration in mice. Mycopathologia, 1984, 85, 75-79.
14. Toth, B.; Erickson, J.; Gannett, P.; Patil, K. Carcinogenesis by the cultivated baked Agaricus bisporus mushroom in mice. Oncol. Rep., 1997, 4, 931-936.
15. Toth, B.; Gannett, P.; Visek, W. J.; Patil, K. Carcinogenesis studies with the lyophilized mushroom Agaricus bisporus in mice. In Vivo, 1998, 12, 239-244.
16. Ross, A. E.; Nagel, D. L.; Toth, B. Occurrence, stability and decomposition of beta-N [gamma-L(+)-glutamyl]-4-hydroxymethylphenylhydrazine (agaritine) from the mushroom Agaricus bisporus. Food Chem. Toxicol., 1982, 20, 903-907.
17. Toth, B.; Erickson, J.; Gannett, P. Lack of carcinogenesis by the baked mushroom Agaricus bisporus in mice: different feeding regimen [corrected. In Vivo, 1997, 11, 227-231.
18. Walton, K.; Coombs, M. M.; Walker, R.; Ioannides, C. Bioactivation of mushroom hydrazines to mutagenic products by mammalian and fungal enzymes. Mutat. Res., 1997, 381, 131-139.
19. Walton, K.; Coombs, M. M.; King, L. J.; Walker, R.; Ioannides, C. Fate of the mushroom hydrazine agaritine in the rat and mouse. Nutr. Cancer, 2000, 37, 55-64.
20. Endo, M.; Beppu, H.; Akiyama, H.; Wakamatsu, K.; Ito, S.; Kawamoto, Y.; Shimpo, K.; Sumiya, T.; Koike, T.; Matsui, T. Agaritine purified from Agaricus blazei Murrill exerts anti-tumor activity against leukemic cells. Biochim. Biophys. Acta, 2010, 1800, 669-673.
21. Chen, S.; Oh, S. R.; Phung, S.; Hur, G.; Ye, J. J.; Kwok, S. L.; Shrode, G. E.; Belury, M.; Adams, L. S.; Williams, D. Antiaromatase activity of phytochemicals in white button mushrooms (Agaricus bisporus). Cancer Res., 2006, 66, 12026-12034.
22. Adams, L. S.; Phung, S.; Wu, X.; Ki, L.; Chen, S. White button mushroom (Agaricus bisporus) exhibits antiproliferative and proapoptotic properties and inhibits prostate tumor growth in athymic mice. Nutr. Cancer, 2008, 60, 744-756.
23. Spolar, M. R.; Schaffer, E. M.; Beelman, R. B.; Milner, J. A. Selenium-enriched Agaricus bisporus mushrooms suppress 7,12-dimethlybenz[a]anthracene bioactivation in mammary tissue. Cancer Lett., 1999, 138, 145-150.
24. Wu, D.; Pae, M.; Ren, Z.; Guo, Z.; Smith, D.; Meydani, S. N. Dietary supplementation with white button mushroom enhances natural killer cell activity in C57BL/6 mice. J. Nutr., 2007, 137, 1472-1477.
25. Yu, L.; Fernig, D. G.; Smith, J. A.; Milton, J. D.; Rhodes, J. M. Reversible inhibition of proliferation of epithelial cell lines by Agaricus bisporus (edible mushroom) lectin. Cancer Res., 1993, 53, 4627-4632.
26. Yu, L. G.; Fernig, D. G.; White, M. R.; Spiller, D. G.; Appleton, P.; Evans, R. C.; Grierson, I.; Smith, J. A.; Davies, H.; Gerasimenko, O. V.; Petersen, O. H.; Milton, J. D.; Rhodes, J. M. Edible mushroom (Agaricus bisporus) lectin, which reversibly inhibits epithelial cell proliferation, blocks nuclear localization sequence-dependent nuclear protein import. J. Biol. Chem., 1999, 274, 4890-4899.
27. Firenzuoli, F.; Gori, L.; Lombardo, G. The Medicinal Mushroom Agaricus blazei Murrill: Review of Literature and Pharmaco-Toxicological Problems. Evid Based. Complement. Alternat Med., 2008, 5, 3-15.
28. Lee, Y. L.; Kim, H. J.; Lee, M. S.; Kim, J. M.; Han, J. S.; Hong, E. K.; Kwon, M. S.; Lee, M. J. Oral administration of Agaricus blazei (H1 strain) inhibited tumor growth in a sarcoma 180 inoculation model. Exp. Anim., 2003, 52, 371-375.
29. Ishii, P. L.; Prado, C. K.; Mauro Mde, O.; Carreira, C. M.; Mantovani, M. S.; Ribeiro, L. R.; Dichi, J. B.; Oliveira, R. J. Evaluation of Agaricus blazei in vivo for antigenotoxic, anticarcinogenic, phagocytic and immunomodulatory activities. Regul. Toxicol. Pharmacol., 2011, 59, 412-422.
30. Kim, C. F.; Jiang, J. J.; Leung, K. N.; Fung, K. P.; Lau, C. B. Inhibitory effects of Agaricus blazei extracts on human myeloid leukemia cells. J. Ethnopharmacol., 2009, 122, 320-326.
31. Yu, C. H.; Kan, S. F.; Shu, C. H.; Lu, T. J.; Sun-Hwang, L.; Wang, P. S. Inhibitory mechanisms of Agaricus blazei Murill on the growth of prostate cancer in vitro and in vivo. J. Nutr. Biochem., 2009, 20, 753-764.
32. Kimura, Y.; Kido, T.; Takaku, T.; Sumiyoshi, M.; Baba, K. Isolation of an anti-angiogenic substance from Agaricus blazei Murill: its antitumor and antimetastatic actions. Cancer. Sci., 2004, 95, 758-764.
33. Akiyama, H.; Endo, M.; Matsui, T.; Katsuda, I.; Emi, N.; Kawamoto, Y.; Koike, T.; Beppu, H. Agaritine from Agaricus blazei Murrill induces apoptosis in the leukemic cell line U937. Biochim. Biophys. Acta, 2011, 1810, 519-525.
34. Itoh, H.; Ito, H.; Hibasami, H. Blazein of a new steroid isolated from Agaricus blazei Murrill (himematsutake) induces cell death and morphological change indicative of apoptotic chromatin condensation in human lung cancer LU99 and stomach cancer KATO III cells. Oncol. Rep., 2008, 20, 1359-1361.
35. Su, Z. Y.; Tung, Y. C.; Hwang, L. S.; Sheen, L. Y. Blazeispirol A from Agaricus blazei fermentation product induces cell death in human hepatoma Hep 3B cells through caspase-dependent and caspase-independent pathways. J. Agric. Food Chem., 2011, 59, 5109-5116.
36. Itoh, H.; Ito, H.; Amano, H.; Noda, H. Inhibitory action of a (1->6)-beta-D-glucan-protein complex (F III-2-b) isolated from Agaricus blazei Murill (himematsutake) on Meth A fibrosarcoma-bearing mice and its antitumor mechanism. Jpn. J. Pharmacol., 1994, 66, 265-271.
37. Niu, Y. C.; Liu, J. C.; Zhao, X. M.; Wu, X. X. A low molecular weight polysaccharide isolated from Agaricus blazei suppresses tumor growth and angiogenesis in vivo. Oncol. Rep., 2009, 21, 145-152.
38. Ziliotto, L.; Barbisan, L. F.; Rodrigues, M. A. Lack of chemoprevention of dietary Agaricus blazei against rat colonic aberrant crypt foci. Hum. Exp. Toxicol., 2008, 27, 505-511.
39. Ziliotto, L.; Pinheiro, F.; Barbisan, L. F.; Rodrigues, M. A. Screening for in vitro and in vivo antitumor activities of the mushroom Agaricus blazei. Nutr. Cancer, 2009, 61, 245-250.
40. Yoshimura, K.; Kamoto, T.; Ogawa, O.; Matsui, S.; Tsuchiya, N.; Tada, H.; Murata, K.; Yoshimura, K.; Habuchi, T.; Fukushima, M. Medical mushrooms used for biochemical failure after radical treatment for prostate cancer: an open-label study. Int. J. Urol., 2010, 17, 548-554.
41. Ahn, W. S.; Kim, D. J.; Chae, G. T.; Lee, J. M.; Bae, S. M.; Sin, J. I.; Kim, Y. W.; Namkoong, S. E.; Lee, I. P. Natural killer cell activity and quality of life were improved by consumption of a mushroom extract, Agaricus blazei Murill Kyowa, in gynecological cancer patients undergoing chemotherapy. Int. J. Gynecol. Cancer, 2004, 14, 589-594.
42. Talcott, J. A.; Clark, J. A.; Lee, I. P. Measuring perceived effects of drinking an extract of basidiomycetes Agaricus blazei Murill: a survey of Japanese consumers with cancer. BMC Complement. Altern. Med., 2007, 7, 32.
43. Mukai, H.; Watanabe, T.; Ando, M.; Katsumata, N. An alternative medicine, Agaricus blazei, may have induced severe hepatic dysfunction in cancer patients. Jpn. J. Clin. Oncol., 2006, 36, 808-810.
44. Konishi, H.; Yamanaka, K.; Mizutani, H. Possible case for falsepositive reaction in serum 5-S-cysteinyldopa levels in a patient with malignant melanoma by ingestion of Agaricus blazei Murrill extract. J. Dermatol., 2010, 37, 773-775.
45. Ohno, S.; Sumiyoshi, Y.; Hashine, K.; Shirato, A.; Kyo, S.; Inoue, M. Phase I Clinical Study of the Dietary Supplement, Agaricus blazei Murill, in Cancer Patients in Remission. Evid Based. Complement. Alternat Med., 2011, 2011, 192381.
46. Kurashige, S.; Akuzawa, Y.; Endo, F. Effects of Lentinus edodes, Grifola frondosa and Pleurotus ostreatus administration on cancer outbreak, and activities of macrophages and lymphocytes in mice treated with a carcinogen, N-butyl-N-butanolnitrosoamine. Immunopharmacol. Immunotoxicol., 1997, 19, 175-183.
47. Sarangi, I.; Ghosh, D.; Bhutia, S. K.; Mallick, S. K.; Maiti, T. K. Anti-tumor and immunomodulating effects of Pleurotus ostreatus mycelia-derived proteoglycans. Int. Immunopharmacol., 2006, 6, 1287-1297.
48. Bobek, P.; Galbavy, S. Effect of pleuran (beta-glucan from Pleurotus ostreatus) on the antioxidant status of the organism and on dimethylhydrazine-induced precancerous lesions in rat colon. Br. J. Biomed. Sci., 2001, 58, 164-168.
49. Gu, Y. H.; Sivam, G. Cytotoxic effect of oyster mushroom Pleurotus ostreatus on human androgen-independent prostate cancer PC-3 cells. J. Med. Food, 2006, 9, 196-204.
50. Wu, J. Y.; Chen, C. H.; Chang, W. H.; Chung, K. T.; Liu, Y. W.; Lu, F. J.; Chen, C. H. Anti-Cancer Effects of Protein Extracts from Calvatia lilacina, Pleurotus ostreatus and Volvariella volvacea. Evid Based. Complement. Alternat Med., 2011, 2011, 982368.
51. Lavi, I.; Friesem, D.; Geresh, S.; Hadar, Y.; Schwartz, B. An aqueous polysaccharide extract from the edible mushroom Pleurotus ostreatus induces anti-proliferative and pro-apoptotic effects on HT-29 colon cancer cells. Cancer Lett., 2006, 244, 61-70.
52. Jedinak, A.; Sliva, D. Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway. Int. J. Oncol., 2008, 33, 1307-1313.
53. Sasaki, T.; Takasuka, N. Further study of the structure of lentinan, an anti-tumor polysaccharide from Lentinus edodes. Carbohydr. Res., 1976, 47, 99-104.
54. Sasaki, T.; Takasuka, N.; Chihara, G.; Maeda, Y. Y. Antitumor activity of degraded products of lentinan: its correlation with molecular weight. Gann, 1976, 67, 191-195.
55. Zhang, L.; Li, X.; Xu, X.; Zeng, F. Correlation between antitumor activity, molecular weight, and conformation of lentinan. Carbohydr. Res., 2005, 340, 1515-1521.
56. Chihara, G.; Maeda, Y.; Hamuro, J.; Sasaki, T.; Fukuoka, F. Inhibition of mouse sarcoma 180 by polysaccharides from Lentinus edodes (Berk.) sing. Nature, 1969, 222, 687-688.
57. Maeda, Y. Y.; Hamuro, J.; Chihara, G. The mechanisms of action of anti-tumour polysaccharides. I. The effects of antilymphocyte serum on the anti-tumour activity of lentinan. Int. J. Cancer, 1971, 8, 41-46.
58. Ng, M. L.; Yap, A. T. Inhibition of human colon carcinoma development by lentinan from shiitake mushrooms (Lentinus edodes). J. Altern. Complement. Med., 2002, 8, 581-589.
59. Tanaka, K.; Ishikawa, S.; Matsui, Y.; Tamesada, M.; Harashima, N.; Harada, M. Oral ingestion of Lentinula edodes mycelia extract inhibits B16 melanoma growth via mitigation of regulatory T cellmediated immunosuppression. Cancer. Sci., 2011, 102, 516-521.
60. Ngai, P. H.; Ng, T. B. Lentin, a novel and potent antifungal protein from shitake mushroom with inhibitory effects on activity of human immunodeficiency virus-1 reverse transcriptase and proliferation of leukemia cells. Life Sci., 2003, 73, 3363-3374.
61. Fang, N.; Li, Q.; Yu, S.; Zhang, J.; He, L.; Ronis, M. J.; Badger, T. M. Inhibition of growth and induction of apoptosis in human cancer cell lines by an ethyl acetate fraction from shiitake mushrooms. J. Altern. Complement. Med., 2006, 12, 125-132.
62. Spierings, E. L.; Fujii, H.; Sun, B.; Walshe, T. A Phase I study of the safety of the nutritional supplement, active hexose correlated compound, AHCC, in healthy volunteers. J. Nutr. Sci. Vitaminol. (Tokyo), 2007, 53, 536-539.
63. Kosaka, A.; Wani, T.; Hattori, Y.; Yamashita, A. Effect of lentinan administration of adrenalectomized rats and patients with breast cancer. Gan To Kagaku Ryoho, 1982, 9, 1474-1481.
64. Taguchi, T. Effects of lentinan in advanced or recurrent cases of gastric, colorectal, and breast cancer. Gan To Kagaku Ryoho, 1983, 10, 387-393.
65. Taguchi, T.; Furue, H.; Kimura, T.; Kondo, T.; Hattori, T.; Itoh, I.; Ogawa, N. Results of phase III study of lentinan. Gan To Kagaku Ryoho, 1985, 12, 366-378.
66. deVere White, R. W.; Hackman, R. M.; Soares, S. E.; Beckett, L. A.; Sun, B. Effects of a mushroom mycelium extract on the treatment of prostate cancer. Urology, 2002, 60, 640-644.
67. Wang, W.; Dai, X.; Ouyang, X. Efficacy of Lentinan combined with chemotherapy in advanced non-small cell lung cancer. Zhongguo Fei Ai Za Zhi, 2006, 9, 78-81.
68. Gordon, M.; Bihari, B.; Goosby, E.; Gorter, R.; Greco, M.; Guralnik, M.; Mimura, T.; Rudinicki, V.; Wong, R.; Kaneko, Y. A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. J. Med., 1998, 29, 305-330.
69. Nagashima, Y.; Sanpei, N.; Yamamoto, S.; Yoshino, S.; Tangoku, A.; Oka, M. Evaluation of host immunity and side effects in breast cancer patients treated with adjuvant chemotherapy (FEC therapy). Gan To Kagaku Ryoho, 2005, 32, 1550-1552.
70. Suzuki, I.; Itani, T.; Ohno, N.; Oikawa, S.; Sato, K.; Miyazaki, T.; Yadomae, T. Antitumor activity of a polysaccharide fraction extracted from cultured fruiting bodies of Grifola frondosa. J. Pharmacobiodyn, 1984, 7, 492-500.
71. Ohno, N.; Adachi, Y.; Suzuki, I.; Oikawa, S.; Sato, K.; Ohsawa, M.; Yadomae, T. Antitumor activity of a beta-1,3-glucan obtained from liquid cultured mycelium of Grifola frondosa. J. Pharmacobiodyn, 1986, 9, 861-864.
72. Mayell, M. Maitake extracts and their therapeutic potential. Altern. Med. Rev., 2001, 6, 48-60.
73. Kodama, N.; Asakawa, A.; Inui, A.; Masuda, Y.; Nanba, H. Enhancement of cytotoxicity of NK cells by D-Fraction, a polysaccharide from Grifola frondosa. Oncol. Rep., 2005, 13, 497-502.
74. Takeyama, T.; Suzuki, I.; Ohno, N.; Oikawa, S.; Sato, K.; Ohsawa, M.; Yadomae, T. Host-mediated antitumor effect of grifolan NMF-5N, a polysaccharide obtained from Grifola frondosa. J. Pharmacobiodyn, 1987, 10, 644-651.
75. Suzuki, I.; Itani, T.; Ohno, N.; Oikawa, S.; Sato, K.; Miyazaki, T.; Yadomae, T. Effect of a polysaccharide fraction from Grifola frondosa on immune response in mice. J. Pharmacobiodyn, 1985, 8, 217-226.
76. Li, X.; Rong, J.; Wu, M.; Zeng, X. Anti-tumor effect of polysaccharide from Grifola frondosa and its influence on immunological function. Zhong Yao Cai, 2003, 26, 31-32.
77. Ito, K.; Masuda, Y.; Yamasaki, Y.; Yokota, Y.; Nanba, H. Maitake beta-glucan enhances granulopoiesis and mobilization of granulocytes by increasing G-CSF production and modulating CXCR4/SDF-1 expression. Int. Immunopharmacol., 2009, 9, 1189-1196.
78. Shurin, M. R.; Lu, L.; Kalinski, P.; Stewart-Akers, A. M.; Lotze, M. T. Th1/Th2 balance in cancer, transplantation and pregnancy. Springer Semin. Immunopathol., 1999, 21, 339-359.
79. Inoue, A.; Kodama, N.; Nanba, H. Effect of maitake (Grifola frondosa) D-fraction on the control of the T lymph node Th-1/Th-2 proportion. Biol. Pharm. Bull., 2002, 25, 536-540.
80. Harada, N.; Kodama, N.; Nanba, H. Relationship between dendritic cells and the D-fraction-induced Th-1 dominant response in BALB/c tumor-bearing mice. Cancer Lett., 2003, 192, 181-187.
81. Kodama, N.; Murata, Y.; Nanba, H. Administration of a polysaccharide from Grifola frondosa stimulates immune function of normal mice. J. Med. Food, 2004, 7, 141-145.
82. Kodama, N.; Mizuno, S.; Nanba, H.; Saito, N. Potential antitumor activity of a low-molecular-weight protein fraction from Grifola frondosa through enhancement of cytokine production. J. Med. Food, 2010, 13, 20-30.
83. Deng, G.; Lin, H.; Seidman, A.; Fornier, M.; D'Andrea, G.; Wesa, K.; Yeung, S.; Cunningham-Rundles, S.; Vickers, A. J.; Cassileth, B. A phase I/II trial of a polysaccharide extract from Grifola frondosa (Maitake mushroom) in breast cancer patients: immunological effects. J. Cancer Res. Clin. Oncol., 2009, 135, 1215-1221.
84. Konno, S. Synergistic potentiation of D-fraction with vitamin C as possible alternative approach for cancer therapy. Int. J. Gen. Med., 2009, 2, 91-108.
85. Kodama, N.; Komuta, K.; Nanba, H. Can maitake MD-fraction aid cancer patients? Altern. Med. Rev., 2002, 7, 236-239.
86. Kodama, N.; Komuta, K.; Sakai, N.; Nanba, H. Effects of D-Fraction, a polysaccharide from Grifola frondosa on tumor growth involve activation of NK cells. Biol. Pharm. Bull., 2002, 25, 1647-1650.
87. Kodama, N.; Komuta, K.; Nanba, H. Effect of Maitake (Grifola frondosa) D-Fraction on the activation of NK cells in cancer patients. J. Med. Food, 2003, 6, 371-377.
88. Solomon, C. G. The epidemiology of polycystic ovary syndrome. Prevalence and associated disease risks. Endocrinol. Metab. Clin. North Am., 1999, 28, 247-263.
89. Chen, J. T.; Tominaga, K.; Sato, Y.; Anzai, H.; Matsuoka, R. Maitake mushroom (Grifola frondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. J. Altern. Complement. Med., 2010, 16, 1295-1299.